Abstract
The scenario discussed in this chapter involves the management of castration-resistant prostate cancer (CRPC) in the setting of prior prostatectomy with lymphadenectomy with likely disease recurrence in a pelvic lymph node. Treating this patient is both nuanced and complicated given the rapidly evolving management of advanced prostate cancer and paucity of data guiding salvage lymphadenectomy in the setting of CRPC. Options for treatment include multiple modalities, including systemic therapies (such as chemo- or hormonal therapy) that have proven efficacy in the metastatic CPRC setting, and localized treatment such as radiation or surgery. This chapter aims to outline the issues and reasoning behind various treatment options for patients with CRPC and local disease recurrence and specifically updates evidence related to salvage lymphadenectomy in this setting.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190:429–38.
Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910–4.
Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. Urol Clin North Am. 2001;28:555–65.
Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893–9.
Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.
Daly T, Hickey BE, Lehman M, et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011:CD007234.
Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2007;25:1596–605.
Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.
Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55:374–410.
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68 Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.
Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of Fluciclovine ((18)F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197:676–83.
Murphy DG, Sweeney CJ, Tombal B. “Gotta catch ‘em all’”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol. 2017;72:1–3.
Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8.
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.
Wei XX, Ko EC, Ryan CJ. Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol. 2017;27(6):596–603.
Busch J, Hinz S, Kempkensteffen C, et al. Selective lymph node dissection for castration-resistant prostate cancer. Urol Int. 2012;88:441–6.
Zattoni F, Nehra A, Murphy CR, et al. Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy. Eur Urol Focus. 2016;2:522–31.
Osmonov DK, Aksenov AV, Trick D, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection. BMC Urol. 2016;16:56.
Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002;110:905–11.
Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncologia. 2012;2:215.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Gregg, J.R., Reichard, C., Davis, J. (2018). Resection of Metastatic Cancer in Castration-Resistant Patients. In: Chang, S., Cookson, M. (eds) Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-78646-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-78646-9_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78645-2
Online ISBN: 978-3-319-78646-9
eBook Packages: MedicineMedicine (R0)